Divergent pathways of gene expression are activated by the RAGE ligands S100b and AGE-BSA.
Tools
Tools
Valencia, Jessica, Mone, Manisha, Zhang, Jin, Weetall, Marla, Buxton, Francis and Hughes, Thomas (2004) Divergent pathways of gene expression are activated by the RAGE ligands S100b and AGE-BSA. Diabetes, 53 (3). pp. 743-751. ISSN 0012-1797
Abstract
Activation of the receptor for advanced glycation end products (RAGE) reportedly triggers a variety of proinflammatory responses. However, our previous work revealed that RAGE-binding AGEs free of endotoxin were incapable of inducing vascular cell adhesion molecule-1 (VCAM-1) or tumor necrosis factor-alpha (TNF-alpha) expression. Thus, the objective of this study was to clarify the role of AGEs in cell activation through gene expression profiling using both in vitro and in vivo model systems. Endothelial cells treated with AGE-BSA, previously shown to bind RAGE with high affinity, did not show gene expression changes indicative of an inflammatory response. In contrast, the alternate RAGE ligand, S100b, triggered an increase in endothelial mRNA expression of a variety of immune-related genes. The effects of AGEs were studied in vivo using healthy mice exposed to two different treatment conditions: 1) intravenous injection of a single dose of model AGEs or 2) four intraperitoneal injections of model AGEs (once per day). In both cases, the liver was extracted for gene expression profiling. Both of the short-term AGE treatments resulted in a moderate increase in liver mRNA levels for genes involved in macrophage-based clearance/detoxification of foreign agents. Our findings using AGEs with strong RAGE-binding properties indicate that AGEs may not uniformly play a role in cellular activation.
| Item Type: | Article |
|---|---|
| Related URLs: | |
| Additional Information: | author can archive post-print (ie final draft post-refereeing); On author website, institutional repository or funding body (eg NIH); Publisher's version/PDF cannot be used |
| Keywords: | AGE; advanced glycation end product Ctrl BSA; BSA incubated in the absence of modifying agent EC; endothelial cell HC; hydrocortisone HMEC; human microvascular EC hsRAGE; human soluble RAGE ICAM-1; intercellular adhesion molecule-1 IκBα; inhibitor of nuclear factor-κB IL; interleukin LPS; lipopolysaccharide/endotoxin MHC; major histocompatibility complex RAGE; receptor for AGE Rib BSA; BSA incubated with ribose TF; tissue factor TGF-β; transforming growth factor-β TNF-α; tumor necrosis factor-α; VCAM-1; vascular cell adhesion molecule-1 |
| Related URLs: | |
| Date Deposited: | 14 Dec 2009 13:54 |
| Last Modified: | 31 Jan 2013 01:07 |
| URI: | https://oak.novartis.com/id/eprint/775 |